Progyny, Inc. (NASDAQ:PGNY) Shares Sold by T. Rowe Price Investment Management Inc.

T. Rowe Price Investment Management Inc. reduced its stake in shares of Progyny, Inc. (NASDAQ:PGNY) by 4.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,265,316 shares of the company’s stock after selling 164,729 shares during the quarter. T. Rowe Price Investment Management Inc. owned 3.83% of Progyny worth $56,327,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Quantessence Capital LLC acquired a new position in shares of Progyny in the 4th quarter valued at $243,000. Hsbc Holdings PLC increased its holdings in Progyny by 20.1% in the fourth quarter. Hsbc Holdings PLC now owns 35,095 shares of the company’s stock valued at $603,000 after buying an additional 5,877 shares in the last quarter. Stifel Financial Corp raised its position in shares of Progyny by 48.5% in the fourth quarter. Stifel Financial Corp now owns 71,736 shares of the company’s stock worth $1,237,000 after acquiring an additional 23,425 shares during the period. Thematics Asset Management boosted its stake in shares of Progyny by 3.1% during the 4th quarter. Thematics Asset Management now owns 112,486 shares of the company’s stock worth $1,940,000 after acquiring an additional 3,336 shares in the last quarter. Finally, MetLife Investment Management LLC grew its position in shares of Progyny by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 51,891 shares of the company’s stock valued at $895,000 after acquiring an additional 3,085 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.

Progyny Stock Performance

Shares of Progyny stock opened at $22.76 on Friday. The business’s 50 day moving average price is $21.94 and its 200 day moving average price is $19.05. The company has a market cap of $1.95 billion, a price-to-earnings ratio of 39.24, a PEG ratio of 2.39 and a beta of 1.33. Progyny, Inc. has a one year low of $13.39 and a one year high of $33.84.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on PGNY. BTIG Research upgraded Progyny from a “neutral” rating to a “buy” rating and set a $28.00 price target on the stock in a research report on Monday, March 31st. Canaccord Genuity Group upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research report on Friday, February 28th. Bank of America lifted their target price on shares of Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. raised their price target on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Eight research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $23.64.

Progyny Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.